Explore career opportunities at Radius Health. Discover why working at Radius Health is rewarding and fulfilling. Join our team and make a difference today.
Products TYMLOS® BINOSTO® Funding News & Media Publications Congress Presentations Osteoporosis Publications Careers Patient Assistance Compassionate Use Partnerships Contact Go to homepage Search Search site © 2025 Radius Health, Inc. RADIUS, RADIUSASSIST, TYMLOS and ELADYNOS are registered trademarks...
美国时间2022-12-20,Radius Health, Inc.,一家专注于骨骼健康和肿瘤学的全球生物制药企业,宣布其甲状旁腺激素相关肽 [PTHrP(1-34)] 类似物TYMLOS®(Abaloparatide)已获FDA批准,用于治疗高骨折风险的男性骨质疏松症,或对其他现有疗法无效/不耐受的患者。 此次批准是基于ATOM Ⅲ期试验(BA058-05-019)的积极结果。
© 2025 Radius Health, Inc. RADIUS, RADIUSASSIST, TYMLOS and ELADYNOS are registered trademarks of Radius Health, Inc. All other trademarks are the property of their respective owners X / Twitter LinkedIn YouTube Radius Health is a portfolio company ofGurnet Point Capital,Patient Square Capital...
证券名称Radius Health Inc 证券类型美股 上市场所纳斯达克交易所 上市板块- 发行方式- 首发上市日1993-11-16 首发价格(元)- 首发数量(股)0 首发募资额(元)- 首发主承销商- 货币单位USD 公司名称Radius Recycling, Inc. 注册地址美国俄勒冈州 办公地址299 SW Clay Street, Suite 350, Portland, Oregon, USA ...
An interview with Robert Ward, president and chief executive officer (CEO) of American pharmaceutical company Radius Health Inc. is presented. He provides an overview on the historical background of the company before its initial public offering (IPO). He also emphasizes the significance of IPO ...
All News #Library Europe EU Moment of Truth For Abaloparatide & Advanced Therapy Tab-Cel 11 Oct 2022 // PHARMAINTELLIGENCE Roche hit with another key R&D setback as oral SERD flops in breast cancer 26 Apr 2022 // FIERCEBIOTECH Radius Health, Inc. Announces Acquisition of Orphan Disease Progr...
美国时间2022-12-20,Radius Health, Inc.,一家专注于骨骼健康和肿瘤学的全球生物制药企业,宣布其甲状旁腺激素相关肽 [PTHrP(1-34)] 类似物TYMLOS®(Abaloparatide)已获FDA批准,用于治疗高骨折风险的男性骨质疏松症,或对其他现有疗法无效/不耐受的患者。
(医药健闻2022年6月8日讯)美纳里尼集团和Radius Health, Inc.在美国临床肿瘤学会(ASCO)2022年会上宣布提交EMERALD三期临床试验(NCT03778931)相关数据。在一项非预先指定的ER+/HER2-转移性乳腺癌患者(以前未接受过化疗)亚组分析中,与标准护理内分泌治疗(SOC)相比,艾拉司群显著延长了无进展生存期(PFS)。
除了上述的Radius Health并购事件外，今年6月还发生了两起引人关注的收购交易。6月27日，Epizyme, Inc.拟被Ipsen以1.45 美元的现金价格收购所有流通股，基础的总对价约2.47亿美元（除去约定的CVR外）。据悉，Epizyme,Inc.是一家处于商业阶段的全面一体化生物制药公司，致力于透过创新表观遗传学药物，重新制订癌症...